EXOSYSTEMS Inc. Raises $10M Series A for AI Digital Healthcare

EXOSYSTEMS Inc., a company specializing in AI digital healthcare solutions, has announced it has raised $10,000,000 in its latest funding round from investors. This significant capital infusion marks a crucial step for the company as it continues to advance its innovative offerings in the digital health sector. The company focuses on providing advanced digital therapeutics and electroceutical solutions. EXOSYSTEMS aims to optimize the diagnosis and remote treatment monitoring for conditions like sarcopenia, a progressive muscle disease. Its approach integrates AI digital biomarkers to achieve digital innovation across the entire patient journey, encompassing diagnosis to personalized treatment. The company’s solutions include sarcopenia diagnosis support, remote treatment monitoring systems, AI digital biomarker-based personalized electroceutical solutions, and software-based personalized exercise and rehabilitation treatment (DTx). This investment capital will be strategically allocated to accelerate EXOSYSTEMS’ research and development initiatives, enabling further enhancement of its existing digital health platforms and the creation of new solutions. The funding is also intended to support the expansion of the company’s operational capabilities and its market reach, strengthening its position within the competitive digital therapeutics landscape. The successful fundraising round underscores investor confidence in EXOSYSTEMS' technology and its potential to revolutionize patient care through digital innovation. The capital is poised to drive the company's growth trajectory, supporting its mission to deliver accessible and effective AI-driven healthcare solutions. EXOSYSTEMS plans to continue its focus on innovation, striving to integrate more advanced AI capabilities into its product portfolio and expand its influence in the global digital healthcare market.